DrugPatentWatch Database Preview
Details for Biologics License Application: 103353
» See Plans and Pricing
Summary for BLA: 103353
| Tradename: | NEUPOGEN |
| Applicant: | Amgen |
| Ingredient: | filgrastim |
| Patents: | 218 |
| Approval Date: | Feb 20, 1991 |
| Suppliers: see list | 1 |
Pharmacology for BLA: 103353
| Ingredient-type | Granulocyte Colony-Stimulating Factor Granulocyte-Macrophage Colony-Stimulating Factor |
| Drug Class | Leukocyte Growth Factor |
| Physiological Effect | Increased Myeloid Cell Production |
US Patents for BLA: 103353
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen | NEUPOGEN | filgrastim | VIAL | 103353 | 001 | 1991-02-20 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | RX | search | |
| Amgen | NEUPOGEN | filgrastim | VIAL | 103353 | 001 | 1991-02-20 | Start Trial | 2039-02-26 | RX | search | ||
| Amgen | NEUPOGEN | filgrastim | VIAL | 103353 | 001 | 1991-02-20 | Start Trial | University of the Sciences of Philadelphia (Philadelphia, PA) | 2034-11-21 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
